Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 3 1

Status

Withdrawn 2Completed 2Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 12OTHER 6NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 45Breast Neoplasms 20Myelodysplastic Syndromes 19Prostatic Neoplasms 12Neoplasms 12Leukemia, Myelomonocytic, Chronic 12Carcinoma, Hepatocellular 10Stomach Neoplasms 9Recurrence 9Carcinoma, Non-Small-Cell Lung 8Neoplasm Metastasis 7Esophageal Neoplasms 7Uterine Cervical Neoplasms 6Sarcoma 6Ovarian Neoplasms 6Multiple Myeloma 6Lung Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myeloproliferative Disorders 5Melanoma 5Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell 5Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Myelodysplastic-Myeloproliferative Diseases 4Leukemia, Biphenotypic, Acute 4Cholangiocarcinoma 4Thrombocythemia, Essential 3

Interventions

Dexamethasone 420Lenalidomide 265Cyclophosphamide 246Bortezomib 242Melphalan 192Calcium Dobesilate 166fludarabine phosphate 112daratumumab 103Peripheral Blood Stem Cell Transplantation 99carfilzomib 92Thalidomide 90Filgrastim 88Mycophenolic Acid 82fludarabine 81pomalidomide 80Whole-Body Irradiation 80Busulfan 74Tacrolimus 71Granulocyte Colony-Stimulating Factor 66Cyclosporine 58dexamethasone acetate 56ixazomib 55Antilymphocyte Serum 50dexamethasone 21-phosphate 49auricularum 44isatuximab 40Etoposide 39Radiotherapy 36Stem Cell Transplantation 34Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER × Multiple Myeloma × Injections × Clear all
NCT07247097 2025-11-25

ELDORADO

Massachusetts General Hospital

Phase 2 Not yet recruiting
160 enrolled
Plasma cell

Multiple Myeloma

NCT03602235 2025-10-21

High Dose Ascorbic Acid for Plasma Cell Disorders

University of Iowa

Phase 1 Completed
6 enrolled
Plasma cell

Multiple Myeloma

NCT01125449 2025-05-18

Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease

Situs Cancer Research Center

Phase 2 Withdrawn
Plasma cellSarcoma

Adenocarcinoma, Carcinoma, Multiple Myeloma, Sarcoma, Desmoplastic Small Round Cell Tumor

NCT05438394 2023-04-14

Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM

Peking University People's Hospital

Phase 1 Unknown
24 enrolled
Plasma cell

Multiple Myeloma

NCT04288765 2021-07-09

Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma

Grupo Cooperativo de Hemopatías Malignas

Phase 3 Withdrawn
Plasma cell

Multiple Myeloma

NCT02669615 2018-10-10

Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation

Medical College of Wisconsin

Phase 2 Completed
24 enrolled 6 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡